Friday 21st August 2020

Findings of nintedanib's safety and tolerability published

A team of researchers based in the USA, UK, Germany, Switzerland and Japan sought to examine the results of the SENSCIS trial to assess the safety and tolerability of nintedanib in people with SSc-ILD.

Read Article

Tuesday 4th August 2020

Evidence for utilising role-play workshops for the education of rare diseases

A research team based at Lille University implemented a simulation-based workshop to assess if there would be a positive change in the ability of medical students to recognise Raynaud's and scleroderma.

Read Article

Friday 17th July 2020

The crossroad between scleroderma and Covid-19

The COVID-19 pandemic continues to be, a challenging period of almost everyone’s lives. A team of researchers from the University of Florence and Shantou investigated the potential of Covid-19 complicating interstitial lung disease in scleroderma as well as the effects on routine clinical care and psychosocial implications.

Read Article

Friday 3rd July 2020

Digital Ulcers – Capturing The Patient Experience to Improve Outcomes

Researchers funded by the Scleroderma Clinicals Trials Consortium (SCTC) sought to understand how digital ulcers can affect a person’s life, discussing pain, aggravating factors and practical measures taken when ulcers develop.

Read Article

Friday 26th June 2020

New findings on lenabasum from RESOLVE-1 trial

Lenabasum is a synthetic drug that activates a certain receptor involved in the immune system and in the activity of fibroblasts, which drive fibrosis (scarring), and is particularly useful for diffuse cutaneous scleroderma.

Read Article

Thursday 28th May 2020

Growing up with juvenile scleroderma

What is it really like to grow up with scleroderma? We look at the various ways that this condition can affect our children, both physically and emotionally, as they navigate the path to adulthood.

Read Article

Thursday 28th May 2020

Chronic pain – how to break the cycle and take control

With around 28 million adults now living with chronic pain in the UK, it has become something of a silent epidemic. There are however a number of ways to help reduce its impact upon your life.

Read Article

Tuesday 28th April 2020

Approval of nintedanib for systemic sclerosis-associated interstitial lung disease

Nintedanib, a drug that slows the rate of lung fibrosis, has been approved as a treatment for individuals with systemic sclerosis-associated interstitial lung disease, the first option to have been made available.

Read Article

Friday 17th April 2020

Identifying barriers to exercise

Remaining physically active is important for everyone, but sometimes this is very challenging for the SRUK community. A study set up by the Scleroderma Patient Intervention Network sought to understand what the major barriers and facilitators to exercise are.

Read Article

Thursday 5th March 2020

Novel Coronavirus (COVID-19) advice for our community

Advice from Public Health England on COVID-19 to help you understand the implications if you have scleroderma and Raynaud's.

Read Article